Mazdutide is an investigational dual agonist that activates the glucagon receptor and the GLP-1 receptor. It is being studied for obesity and related metabolic disease.

What did the mazdutide phase 2 trial find?

At 32 weeks, least-squares mean weight change was -7.3% with the 3-to-6 mg regimen, -15.6% with 10 mg, and -18.1% with 16 mg, compared with -0.9% with placebo.

Was mazdutide approved by the FDA in this study?

No. This was a phase 2 clinical trial, not an FDA approval decision. The findings are investigational efficacy and safety results.

How does mazdutide differ from semaglutide and tirzepatide?

Semaglutide primarily activates the GLP-1 receptor, while tirzepatide activates GLP-1 and GIP receptors. Mazdutide activates GLP-1 and glucagon receptors.

What were the main mazdutide side effects?

Gastrointestinal adverse events were the most common and were generally mild to moderate. Discontinuation because of adverse events was most frequent in the 16 mg group, reaching 20%.

Why is the U.S. mazdutide trial important?

It provides controlled U.S. clinical data for a glucagon/GLP-1 dual agonist across multiple dose levels and helps evaluate how the findings translate to U.S. adults with obesity.

Does the trial prove mazdutide is better than semaglutide or tirzepatide?

No. The study compared mazdutide with placebo, not directly with semaglutide or tirzepatide. Cross-trial comparisons are limited by differences in populations, doses, durations, endpoints, and designs.

Topics
Start Here
Compounds
Tools
Articles
Search

Topics
Start Here
Compounds
Tools
Articles
Search

Mazdutide Phase 2 Trial: What the U.S. Results Mean for Next-Generation Obesity Drugs

By GLP1Place Research Team / August 21, 2026

Subscribe to continue reading

Subscribe to get access to the rest of this post and other subscriber-only content.

Type your email…

Already a subscriber?

FDA GLP-1 Import Alert Targets Adulterated APIs

FDA Peptide Warning Letters: RUO and Intended Use in 2026

Research Tools

GLP1Place

Independent educational research hub for GLP-1 receptor agonists, research peptides, and nootropic compounds. Not medical advice.

Compound data is sourced from published research and public literature. Always verify independently. See full disclaimer.

Scroll to Top